Analytical Quality by Design (AQbD) A Comprehensive Review of Modern Analytical Method Development

Abstract

Quality by Design (QbD) represents a paradigmatic shift in pharmaceutical analytical method development, transitioning from empirical trial-and-error approaches to systematic, science-based methodologies. This comprehensive review examines the principles, implementation strategies, and regulatory framework of Analytical Quality by Design (AQbD), with emphasis on ICH Q14 and Q2(R2) guidelines effective 2024. The AQbD framework encompasses the Analytical Target Profile (ATP), Critical Quality Attributes (CQAs), Critical Method Parameters (CMPs), and Method Operable Design Region (MODR), collectively ensuring robust, fit-for-purpose analytical procedures throughout their lifecycle. Design of Experiments (DoE) serves as the cornerstone methodology for systematic optimization, enabling multivariate assessment of method parameters and their interactions. This review synthesizes current knowledge on risk assessment tools (Ishikawa diagrams, Failure Mode effect Analysis), optimization strategies (response surface methodology, factorial designs), and regulatory expectations for enhanced versus traditional approaches. Nine case studies demonstrate practical AQbD implementation across chromatographic, spectroscopic, and bioanalytical techniques. The article addresses lifecycle management considerations, including method transfer, continuous improvement, and post-approval change protocols under ICH Q12 frameworks. Emerging trends in real-time release testing, process analytical technology integration, and multivariate analytical procedures are examined. This review provides pharmaceutical scientists with comprehensive guidance for implementing QbD principles in analytical method development,